NM8074 ( DrugBank: - )


2 diseases
IDDisease name (Link within this page)Number of trials
62Paroxysmal nocturnal hemoglobinuria3
109Atypical hemolytic uremic syndrome1

62. Paroxysmal nocturnal hemoglobinuria


Clinical trials : 292 Drugs : 151 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 108
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05731050
(ClinicalTrials.gov)
June 20251/2/2023Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)A Phase II, Open Label, Multi Dose Study of NM8074 in Soliris-Treated Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)PNH - Paroxysmal Nocturnal HemoglobinuriaDrug: NM8074NovelMed TherapeuticsNULLNot yet recruiting18 Years65 YearsAll6Phase 2NULL
2NCT05646524
(ClinicalTrials.gov)
November 202330/11/2022Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor TherapyA Phase II, Open-Label Study of NM8074 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal HemoglobinuriaDrug: NM8074NovelMed TherapeuticsNULLNot yet recruiting18 YearsN/AAll12Phase 2NULL
3NCT05646563
(ClinicalTrials.gov)
September 202330/11/2022Study of NM8074 in Adult PNH Patients With Inadequate Response to SolirisA Phase II, Open-Label Study of NM8074 in Soliris®-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal HemoglobinuriaDrug: NM8074;Drug: SolirisNovelMed TherapeuticsNULLNot yet recruiting18 YearsN/AAll12Phase 2NULL

109. Atypical hemolytic uremic syndrome


Clinical trials : 114 Drugs : 36 - (DrugBank : 7) / Drug target genes : 3 - Drug target pathways : 11
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05684159
(ClinicalTrials.gov)
June 20244/1/2023Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic MicroangiopathyA Phase II, Open-Label Study of NM8074 in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)aHUS - Atypical Hemolytic Uremic SyndromeDrug: NM8074NovelMed TherapeuticsNULLNot yet recruiting18 Years65 YearsAll12Phase 2NULL